In summary, our study demonstrated that IHCH9033, a novel class I HDAC inhibitor, exhibited significant antitumor activity in FLT3-ITD AML, targeting both acquired-resistant AML cell lines and primary-resistant patient samples, through the modulation of DNA damage and repair response. The gene discussed is FLT3; the disease is acute myeloid leukemia.